Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Genetics, |
RCV002221414 | SCV002498679 | uncertain significance | Severe combined immunodeficiency due to CARMIL2 deficiency | 2021-08-10 | criteria provided, single submitter | clinical testing | This sequence change is predicted to replace leucine with proline at codon 309 of the CARMIL2 protein (p.(Leu309Pro)). The leucine residue is moderately conserved (100 vertebrates, UCSC), and is located in the leucine rich LRR 5 repeat. There is a moderate physicochemical difference between leucine and proline. The variant is present in a large population cohort at a frequency of 0.0009% (2/213,250 alleles, 0 homozygotes in gnomAD v2.1). It has been identified with a likely pathogenic variant (phase unknown) in an individual with chronic warts and skin infections since childhood (Royal Melbourne Hospital). Multiple lines of computational evidence have conflicting predictions for the missense substitution (3/6 algorithms deleterious). Based on the classification scheme RMH Modified ACMG Guidelines v1.4.0, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: PM2_Supporting, PM3_Supporting. |